Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists-Reference-Cited by-同舟云学术

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists

Published:2019-09-01 Issue:9 Volume:29 Page:1173-1191
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Sinha Rohit A.¹,Bruinstroop Eveline²³,Singh Brijesh K.²,Yen Paul M.²⁴

Affiliation:

1. Department of Endocrinology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.

2. Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, Singapore, Singapore.

3. Department of Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

4. Division of Endocrinology, Metabolism, and Nutrition, Department of Medicine, Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2018.0664

Reference172 articles.

1. Liver lipid metabolism

2. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease

3. Biochemical controls of liver cholesterol biosynthesis

4. Blood Cholesterol Values in Hyperthyroidism and Hypothyroidism — Their Significance

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Levothyroxine and Non-alcoholic Fatty Liver Disease: A Mini Review;Mini-Reviews in Medicinal Chemistry;2024-12

2. Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets;Biochemical Pharmacology;2024-09

3. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis;Scientific Reports;2024-08-26

4. Studio di fase 3 sull’uso del resmetirom nella NASH con fibrosi epatica;L'Endocrinologo;2024-08

5. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis;Endocrine Practice;2024-07